IP trou­ble de­fers launch of Novo's long-act­ing he­mo­phil­ia ther­a­py

Long-act­ing he­mo­phil­ia ther­a­py Es­pe­r­oct has won FDA ap­proval, but US pa­tients will have to wait un­til next year to ac­cess it, in a blow for mak­er No­vo Nordisk which is look­ing to stave off Roche’s re­cent­ly launched ri­val ther­a­py Hem­li­bra.

He­mo­phil­ia A, or clas­sic he­mo­phil­ia, is a ge­net­ic dis­or­der caused by a miss­ing or de­fec­tive clot­ting pro­tein called fac­tor VI­II that caus­es pro­longed bleed­ing or in­ter­nal bleed­ing. To man­age symp­toms, an in­tra­venous in­jec­tion com­pris­ing the clot­ting fac­tor is usu­al­ly ad­min­is­tered.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER